Eye drops could replace needles for blinding eye disease?

NCT ID NCT06704009

Completed Disease control Sponsor: NexThera Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested NT-101 eye drops in 20 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study aimed to check safety and see if the drops could reduce fluid buildup and improve vision. Participants received either a low or high dose of the eye drops for 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NT-101 topical ophthalmic solution (eye drops)
What this could lead to: If successful, this could point toward a non-invasive eye drop treatment for wet AMD, potentially reducing the need for frequent eye injections.
What could go wrong: This is a very early, small trial (20 people) focused on safety. It is not designed to prove the treatment works, and many early-stage eye drop therapies fail to show benefit in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Duke Eye Center

Durham, North Carolina, 27705, United States
Elman Retina Group

Rosedale, Maryland, 21237, United States
Erie Retina Research

Erie, Pennsylvania, 16505, United States
Texas Retina Associates

Dallas, Texas, 75231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.